Nasdaq

Triple-Gene Presented Preliminary Phase 1 Trial Data of Investigational Multigenic Therapeutic Candidate INXN-4001 for Treatment of Heart Failure at American Heart Association ...

GERMANTOWN, Md., Nov. 18, 2019 /PRNewswire/ -- Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), yesterday ...
Nasdaq

Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN-4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure

GERMANTOWN, Md., Nov. 7, 2019 /PRNewswire/ -- Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), today announced ...
Nature

Multigenic traits and risk assessment in pharmacology: a population approach

Nebert and Menon introduce their paper by writing: ‘Pharmacogenetic differences can be 10- to more than 40-fold between individuals within an ‘ethnic’ group, while the mean variation between ethnic ...
WOOD-TV

OspreyBio Completes Development of the Bird of Prey platform, Greatly Simplifying Building of Complex Multigenic Vectors

FREDERICK, MD, USA, April 30, 2024 /EINPresswire.com/ -- Osprey BioScience, LLC, a gene and cell therapy biotools company and subsidiary of privately-held BioSolution ...